With The End Of Pfizergan, Pfizer Has To Grow It Alone
This article was originally published in The Pink Sheet Daily
Executive Summary
Investors are wondering what Pfizer might do next – and especially whether or not it will split – after the company is outmaneuvered by the US government and ends its ambition to merge with Allergan.
You may also be interested in...
Death And Tax Inversion: Policy Fight Won't Go Away, Now Spawning Lawsuits
US Chamber of Commerce wants court to eliminate IRS rule that blocked Pfizer's acquisition of Allergan; AbbVie hit with second suit over its 2014 proposed acquisition of Shire.
Pfizer Oncology Strategy: An Investment Starts To Pay Off
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
Pfizer’s Biosimilar Strategy Might Be Working
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: